Vol 9, No 4 (2005)
Original paper
Published online: 2005-08-05

open access

Page views 583
Article views/downloads 1473
Get Citation

Connect on Social Media

Connect on Social Media

Effect of 6 weeks treatment with nebivolol on blood pressure reduction and echocardiographic indices in patients with essential hypertension

Elżbieta Florczak, Magdalena Makowiecka-Cieśla, Anna Klisiewicz, Bogna Puciłowska, Rafał Baranowski, Iwona Korzeniowska-Kubacka, Katarzyna Paschalis-Purtak, Hanna Janaszek-Sitkowska, Aleksander Prejbisz, Ewelina Mikocka, Andrzej Januszewicz, Piotr Hoffman
Nadciśnienie tętnicze 2005;9(4):243-251.

Abstract

Background The results of clinical studies comparing antihypertensive efficacy of newer and older beta blockers and their effect on echocardiographic indices are inconclusive. The aim of the study was to evaluate the effect of nebivolol on blood pressure reduction and on selected echocardiographic indices in patients with essential hypertension. The effect of treatment on exercise tolerance was also investigated.
Material and methods The study included 76 male patients with mild to moderate (ESH/ESC: grade 1 and 2) essential hypertension (mean age: 43.6 ± 8.2 years). In all subjects at baseline and after 6 weeks of nebivolol treatment (5 mg once daily) or atenolol (50 mg once daily) (39 and 37 pts respectively) ABPM, Echo, ECG Holter and exercise test were performed.
Results In the nebivolol group SBP and DBP reduction was noticed in 87% and 69% of patients with essential hypertension. Based on ABPM mean SBP and DBP during the whole day, daytime and nighttime decreased: 13 ± 8/8 ± 8 mm Hg, 14 ± 9/10 ± 7 mm Hg and 9 ± 8/6 ± 8 mm Hg respectively (p < 0.01 for all differences).
In the nebivolol group E wave was increased between two examinations from 0.75 ± 0.15 m/s to 0.81 ± 0.2 m/s (p = 0.05), there were no significant changes in A wave 0.66 ± 0.08 m/s vs. 0.64 ± 0.1 m/s (NS).
Ratio E/A was increased during the time of observation from 1.14 ± 0.25 to 1.3 ± 0.23 (p < 0.001).
During the exercise test in the nebivolol group maximal SBP and DBP decreased by 18 ± 26 mm Hg (p < 0.001) and 3 ± 14 mm Hg (NS) respectively after 6 weeks of treatment.
Conclusions Our results indicate high antihypertensive efficacy of nebivolol in patients with essential hypertension. We also observed an improvement of selected echocardiographic indices. Nebivolol was not impairing the exercise tolerance in patients with essential hypertension.

Article available in PDF format

View PDF (Polish) Download PDF file